(Q36787283)

16 August 2017

title

Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder (English)

1 reference

attention deficit hyperactivity disorder

16 August 2017

1 reference

0 references

author name string

Richard H Weisler

series ordinal

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Pharmacotherapy

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

745-758

1 reference

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Assessment of adherence measures with different stimulants among children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Selective imaging strategies for the diagnosis of appendicitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.745

21 January 2018

Identifiers

DOI

10.1517/14656566.8.6.745

1 reference

16 August 2017

1 reference